Bell M R, Meredith D J, Gill P G
Aust N Z J Med. 1985 Apr;15(2):235-40. doi: 10.1111/j.1445-5994.1985.tb04015.x.
Fifteen patients with malignant teratoma and twelve with squamous cancer of the head and neck received treatment with bleomycin. Routine measurements of carbon monoxide diffusing capacity (DLco) were performed. Both groups showed a gradual fall of similar magnitude in their DLco measurements during treatment. No patient in the group with squamous cancer developed clinical or radiological evidence of major pulmonary toxicity. Two of the teratoma patients suffered fatal pulmonary toxicity and their DLco measurements before any signs of major pulmonary toxicity were no different from the measurements of those patients who remained free of major clinical toxicity. The two patients who died both showed a sustained reduction in renal function during chemotherapy which may have been a major risk factor in the development of severe clinical toxicity. The magnitude of the decline in DLco in this series was not a useful predictor of those patients who developed severe and radiological toxicity.
15例恶性畸胎瘤患者和12例头颈部鳞状癌患者接受了博来霉素治疗。进行了一氧化碳弥散量（DLco）的常规测量。两组在治疗期间的DLco测量值均呈相似幅度的逐渐下降。鳞状癌组中没有患者出现严重肺部毒性的临床或影像学证据。两名畸胎瘤患者发生了致命的肺部毒性，在出现任何严重肺部毒性迹象之前，他们的DLco测量值与未出现严重临床毒性的患者的测量值没有差异。两名死亡患者在化疗期间肾功能均持续下降，这可能是发生严重临床毒性的主要危险因素。该系列中DLco下降的幅度并非发生严重影像学毒性患者的有效预测指标。
